Accessibility Statement Skip Navigation
  • Resources
  • Blog
  • Journalists
  • +44 (0)20 7454 5110
  • Client Login
  • Send a Release
Return to PR Newswire homepage
  • News
  • Products
  • Contact
When typing in this field, a list of search results will appear and be automatically updated as you type.

Searching for your content...

No results found. Please change your search terms and try again.
  • News in Focus
      • Browse News Releases

      • All Public Company News
      • All Multimedia News
      • View All News Releases

      • Regulatory News

      • D/A/CH Regulatory News
      • UK Regulatory News
      • View All Regulatory News

  • Business & Money
      • Auto & Transportation

      • Aerospace & Defense
      • Air Freight
      • Airlines & Aviation
      • Automotive
      • Maritime & Shipbuilding
      • Railroads & Intermodal Transportation
      • Supply Chain/Logistics
      • Transportation, Trucking & Railroad
      • Travel
      • Trucking & Road Transportation
      • View All Auto & Transportation

      • Business Technology

      • Blockchain
      • Broadcast Tech
      • Computer & Electronics
      • Computer Hardware
      • Computer Software
      • Data Analytics
      • Electronic Commerce
      • Electronic Components
      • Electronic Design Automation
      • Financial Technology
      • High Tech Security
      • Internet Technology
      • Nanotechnology
      • Networks
      • Peripherals
      • Semiconductors
      • View All Business Technology

      • Entertain­ment & Media

      • Advertising
      • Art
      • Books
      • Entertainment
      • Film & Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • View All Entertain­ment & Media

      • Financial Services & Investing

      • Accounting News & Issues
      • Acquisitions, Mergers & Takeovers
      • Banking & Financial Services
      • Bankruptcy
      • Bond & Stock Ratings
      • Conference Call Announcements
      • Contracts
      • Cryptocurrency
      • Dividends
      • Earnings
      • Earnings Forecasts & Projections
      • Financing Agreements
      • Insurance
      • Investments Opinions
      • Joint Ventures
      • Mutual Funds
      • Private Placement
      • Real Estate
      • Restructuring & Recapitalisation
      • Sales Reports
      • Shareholder Activism
      • Shareholder Meetings
      • Stock Offering
      • Stock Split
      • Venture Capital
      • View All Financial Services & Investing

      • General Business

      • Awards
      • Commercial Real Estate
      • Corporate Expansion
      • Earnings
      • Environmental, Social and Governance (ESG)
      • Human Resource & Workforce Management
      • Licensing
      • New Products & Services
      • Obituaries
      • Outsourcing Businesses
      • Overseas Real Estate (non-US)
      • Personnel Announcements
      • Real Estate Transactions
      • Residential Real Estate
      • Small Business Services
      • Socially Responsible Investing
      • Surveys, Polls & Research
      • Trade Show News
      • View All General Business

  • Science & Tech
      • Consumer Technology

      • Artificial Intelligence
      • Blockchain
      • Cloud Computing/Internet of Things
      • Computer Electronics
      • Computer Hardware
      • Computer Software
      • Consumer Electronics
      • Cryptocurrency
      • Data Analytics
      • Electronic Commerce
      • Electronic Gaming
      • Financial Technology
      • Mobile Entertainment
      • Multimedia & Internet
      • Peripherals
      • Social Media
      • STEM (Science, Tech, Engineering, Math)
      • Supply Chain/Logistics
      • Wireless Communications
      • View All Consumer Technology

      • Energy & Natural Resources

      • Alternative Energies
      • Chemical
      • Electrical Utilities
      • Gas
      • General Manufacturing
      • Mining
      • Mining & Metals
      • Oil & Energy
      • Oil & Gas Discoveries
      • Utilities
      • Water Utilities
      • View All Energy & Natural Resources

      • Environ­ment

      • Conservation & Recycling
      • Environmental Issues
      • Environmental Policy
      • Environmental Products & Services
      • Green Technology
      • Natural Disasters
      • View All Environ­ment

      • Heavy Industry & Manufacturing

      • Aerospace & Defence
      • Agriculture
      • Chemical
      • Construction & Building
      • General Manufacturing
      • HVAC (Heating, Ventilation & Air-Conditioning)
      • Machinery
      • Machine Tools, Metalworking & Metallurgy
      • Mining
      • Mining & Metals
      • Paper, Forest Products & Containers
      • Precious Metals
      • Textiles
      • Tobacco
      • View All Heavy Industry & Manufacturing

      • Telecomm­unications

      • Carriers & Services
      • Mobile Entertainment
      • Networks
      • Peripherals
      • Telecommunications Equipment
      • Telecommunications Industry
      • VoIP (Voice over Internet Protocol)
      • Wireless Communications
      • View All Telecomm­unications

  • Lifestyle & Health
      • Consumer Products & Retail

      • Animals & Pets
      • Beers, Wines & Spirits
      • Beverages
      • Bridal Services
      • Cannabis
      • Cosmetics & Personal Care
      • Fashion
      • Food & Beverages
      • Furniture & Furnishings
      • Home Improvement
      • Household, Consumer & Cosmetics
      • Household Products
      • Jewellery
      • Non-Alcoholic Beverages
      • Office Products
      • Organic Food
      • Product Recalls
      • Restaurants
      • Retail
      • Supermarkets
      • Toys
      • View All Consumer Products & Retail

      • Entertain­ment & Media

      • Advertising
      • Art
      • Books
      • Entertainment
      • Film & Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • View All Entertain­ment & Media

      • Health

      • Biometrics
      • Biotechnology
      • Clinical Trials & Medical Discoveries
      • Dentistry
      • FDA Approval
      • Fitness/Wellness
      • Health Care & Hospitals
      • Health Insurance
      • Infection Control
      • International Medical Approval
      • Medical Equipment
      • Medical Pharmaceuticals
      • Mental Health
      • Pharmaceuticals
      • Supplementary Medicine
      • View All Health

      • Sports

      • General Sports
      • Outdoors, Camping & Hiking
      • Sporting Events
      • Sports Equipment & Accessories
      • View All Sports

      • Travel

      • Amusement Parks & Tourist Attractions
      • Gambling & Casinos
      • Hotels & Resorts
      • Leisure & Tourism
      • Outdoors, Camping & Hiking
      • Passenger Aviation
      • Travel Industry
      • View All Travel

  • Policy & Public Interest
      • Policy & Public Interest

      • Animal Welfare
      • Corporate Social Responsibility
      • Economic News, Trends & Analysis
      • Education
      • Environmental
      • European Government
      • Labour & Union
      • Natural Disasters
      • Not For Profit
      • Public Safety
      • View All Policy & Public Interest

  • People & Culture
      • People & Culture

      • Aboriginal, First Nations & Native American
      • African American
      • Asian American
      • Children
      • Diversity, Equity & Inclusion
      • Hispanic
      • Lesbian, Gay & Bisexual
      • Men's Interest
      • People with Disabilities
      • Religion
      • Senior Citizens
      • Veterans
      • Women
      • View All People & Culture

  • Overview
  • Distribution
  • Paid Placement
  • Multichannel Amplification
  • Disclosure Services
  • SocialBoost
  • Rooms
    • MediaRoom
    • ESG Rooms
  • AI Tools
  • General Enquiries
  • Media Enquiries
  • Partnerships
  • Hamburger menu
  • Cision PR Newswire UK provides press release distribution, targeting, monitoring, and marketing services
  • Send a Release
    • Phone

    • +44 (0)20 7454 5110 from 8 AM - 5:30 PM GMT

    • ALL CONTACT INFO
    • Contact Us

      +44 (0)20 7454 5110
      from 8 AM - 5:30 PM GMT

  • Client Login
  • Send a Release
  • Resources
  • Blog
  • Journalists
  • News in Focus
    • Browse News Releases
    • Regulatory News
  • Business & Money
    • Auto & Transportation
    • Business Technology
    • Entertain­ment & Media
    • Financial Services & Investing
    • General Business
  • Science & Tech
    • Consumer Technology
    • Energy & Natural Resources
    • Environ­ment
    • Heavy Industry & Manufacturing
    • Telecomm­unications
  • Lifestyle & Health
    • Consumer Products & Retail
    • Entertain­ment & Media
    • Health
    • Sports
    • Travel
  • Policy & Public Interest
    • Policy & Public Interest
  • People & Culture
    • People & Culture
  • Client Login
  • Send a Release
  • Resources
  • Blog
  • Journalists
  • Overview
  • Distribution
  • Paid Placement
  • Multichannel Amplification
  • Disclosure Services
  • Cision Communications Cloud®
  • AI Tools
  • Client Login
  • Send a Release
  • Resources
  • Blog
  • Journalists
  • General Enquiries
  • Media Enquiries
  • Partnerships
  • Client Login
  • Send a Release
  • Resources
  • Blog
  • Journalists

Relapses of Brain Tumor to Push Sales of Glioblastoma Multiforme Treatment Past US$ 7 Bn by 2032

This image opens in the lightbox

News provided by

Fact.MR

05 Apr, 2022, 16:30 GMT

Share this article

Share toX

Share this article

Share toX

Rising Demand for Radiotherapy Treatment to Drive Glioblastoma Multiforme Treatment Market at 10.9% CAGR

Fact.MR's market study on the global glioblastoma multiforme treatment market probes into the prevailing factors such key challenges and opportunities that are expected to influence sales of glioblastoma multiforme treatment. The report also delves deeper into the latest trends and dynamics across multiple segments within the market including treatment, drug class, application, and regions.

NEW YORK, April 5, 2022 /PRNewswire/ -- The global glioblastoma multiforme treatment market was valued at around US$ 2.6 Bn in 2021. According to Fact.MR, overall sales of glioblastoma multiforme treatment are expected to total US$ 7 Bn, exhibiting growth at a CAGR of 10.1% during 2022-2032.

Growing awareness regarding the risks of developing glioblastoma multiforme with age in countries such as the U.S., the U.K, China, and India is likely to bolster the need for glioblastoma multiforme treatment.

Rising mortality rate related to glioblastoma multiforme is projected to increase the development of novel biologics, immunotherapy, small molecules and drugs. This is projected to create growth prospects in the market.

For Critical Insights on this Market, Request for More Info at:

https://www.factmr.com/connectus/sample?flag=S&rep_id=7187

Prevalence of variations in patient-to-patient treatment techniques and heterogeneity is spurring demand for personalized treatments. This is likely to boost glioblastoma multiforme treatment sales.

Similarly, rising focus on research and development activities in molecular biotechnology and gene therapy for cancer and related diseases is underpinning the need for effective treatments. Hence, the adoption of glioblastoma multiforme treatment across the healthcare sector is increasing.

In addition to this, the introduction of favorable reimbursement policies simplifies the access to advanced medical facilities. Driven by this, sales in the glioblastoma multiforme treatment are projected to surge in the forthcoming years. 

Moreover, the development of a special class by the U.S. Food and Drug Administration (FDA) for investigational drugs is projected to speed up the approval and marketing of latest therapeutics. This will, in turn, create remunerative opportunities for market players.

Report Attributes

Details

Base Year Value (2021A)

US$ 2.6 Bn

Projected Year Value (2032F)

US$ 7 Bn

Global Growth Rate (2022-2032)

CAGR 10.1%

Key Takeaways:

  • In terms of treatment, demand in the radiation therapy segment is estimated to increase at a CAGR of 10.9%.
  • Based on application, the hospital segment is projected to exhibit growth at 10.8% CAGR during 2022-2032.
  • North America is expected to dominate the market, accounting for over 40% of the total market share.
  • Asia Pacific is expected to register highest CAGR owing to increasing awareness about glioblastoma multiforme treatment in the region.
  • Glioblastoma multiforme treatment market size is anticipated to grow 2.8X during the forecast period, reaching nearly US$ 7 Bn by 2032.

Growth Drivers:

  • Growing incidence of oncological diseases among individuals of all age groups, especially the elderly, is projected to propel demand in the market.
  • Increasing incidence of recurrence of gliomas and brain tumors is anticipated to boost sales.

Restraints:

  • Limited availability of effective treatments to avoid the recurrence of tumors will constrain the demand for glioblastoma multiforme treatment.
  • Increasing side-effects associated with the glioblastoma multiforme treatment might hinder the growth in the market.

Get Customization on this Report for Specific Research Solutions

https://www.factmr.com/connectus/sample?flag=RC&rep_id=7187

Competitive Landscape:

Prominent players in the global glioblastoma multiforme treatment market are investing in advanced technological procedures to develop effective treatments against glioblastoma multiforme. Additionally, players are adopting inorganic business strategies including mergers, acquisitions, and collaborations to expand their global presence. For instance:

  • In July 2020, Denovo Biopharma got the U.S. Food & Drug Administration (FDA) approval for its phase 2b clinical trial on an investigative combination therapy for the treatment of recently diagnosed glioblastoma multiforme patients.
  • In April 2021, Lineage Cell Therapeutics licensed its allogeneic VAC cancer immunotherapy platform to Immunomic Therapeutics. As per the agreement Lineage will be entitled to receive direct payment of US$ 2 Mn, followed by a total of US$ 67 Mn in commercial and development milestones.

Key Companies Profiled by Fact.MR

  • F. Hoffmann-La Roche Ltd.
  • Merck & Co., Inc.
  • Teva Pharmaceutical Industries Ltd.
  • Amgen, Inc.
  • Pfizer Inc.
  • Amgen, Inc.
  • Amneal Pharmaceuticals
  • Karyopharm Therapeutics, Inc.
  • Sun Pharmaceutical Industries Ltd.
  • Arbor Pharmaceuticals, LLC
  • Sumitomo Dainippon Pharma Oncology, Inc.

More Valuable Insights on Glioblastoma Multiforme Treatment Market

In the latest study, Fact.MR's offers in-detailed insights on the global glioblastoma multiforme treatment market by scrutinizing the key growth drivers, historical outlook, and unbiased analysis for the forecast period of 2022 to 2032. This study also covers the opportunities and challenges affecting the growth in the glioblastoma multiforme treatment market through detailed segmentation as follows:

By Treatment:

  • Surgery
  • Radiation Therapy
  • Chemotherapy
  • Targeted Therapy
  • Tumor Treating Field (TTF) Therapy
  • Immunotherapy

By Drug Class:

  • Temozolomide
  • Bevacizumab
  • Carmustine Wafers
  • Other Drug Classes
  • Lomustine

By Application:

  • Hospitals
  • Clinics
  • Ambulatory Surgical Centers

By Region:

  • North America
  • Latin America
  • Europe
  • Asia Pacific (APAC)
  • Middle East and Africa (MEA)

Key Questions Covered in the Glioblastoma Multiforme Treatment Market Report

  • At what rate will the global glioblastoma multiforme treatment market grow until 2032?
  • What is the projected market value of glioblastoma multiforme treatment market in 2022?
  • Which are the factors restraining the growth of the glioblastoma multiforme treatment market?
  • Which are key factors propelling the growth in the global glioblastoma multiforme treatment market?
  • Who are the leading players operating in the global glioblastoma multiforme treatment market?
  • What is expected market revenue of global glioblastoma multiforme treatment market during the forecast period?

Explore Fact.MR's Coverage on the Healthcare Domain

Blood Cancer Diagnostics Market: The blood cancer diagnostics market is projected to benefit from increasing funding from the government and other institutions on the research and development activities for blood cancer diagnostics. Likewise, growing prevalence of leukemia and lymphoma is estimated to boost the demand for blood cancer diagnostics.

Peritoneal Cancer Treatment Market: Demand for peritoneal cancer treatment is expected to surge owing to high incidence of ovarian and peritoneal cancer in women. In addition to this, growing awareness regarding the need for regular health check-ups is projected propel sales of peritoneal cancer treatment, thereby driving the market.

Genitourinary Cancers Treatment Market: Increasing incidence of genitourinary cancers, especially the geriatric population, is boosting demand for genitourinary cancers treatment. Also, growing need for third generation drugs for improving the survival rate is projected to boost sales of genitourinary cancers treatment.

About Fact.MR

Fact.MR is a market research and consulting agency with deep expertise in emerging market intelligence. Spanning a wide range – from automotive & industry 4.0 to healthcare, chemical, and materials, to even the most niche categories. 80% of Fortune 1000's trusts us in critical decision making.

Contact: 

Mahendra Singh
US Sales Office
11140 Rockville Pike
Suite 400
Rockville, MD 20852
United States
Tel: +1 (628) 251-1583
E: sales@factmr.com

Logo: https://mma.prnewswire.com/media/713666/FactMR_Logo.jpg

Modal title

Also from this source

Bisabolene Market is Forecasted to Reach US$ 4.6 Million by 2034, Expanding at a CAGR of 3.9% | Fact.MR Report

According to a new research report published by Fact.MR, the global Bisabolene Market was valued at US$ 3 million in 2023 and has been forecasted to...

Hyaluronic Acid Raw Material Market is projected to grow at a CAGR of 5.2%, Reaching a value of $11.7 billion by 2034 | Fact.MR Report

The global Hyaluronic Acid Raw Material Market has been valued at US$ 7.05 billion in 2024, as stated in the recently updated industry analysis by...

More Releases From This Source

Explore

Health Care & Hospitals

Health Care & Hospitals

Medical Pharmaceuticals

Medical Pharmaceuticals

News Releases in Similar Topics

Contact PR Newswire

  • +44 (0)20 7454 5110
    from 8 AM - 5:30 PM GMT
  • General Enquiries
  • Media Enquiries
  • Partnerships

Products

  • Content Distribution
  • Multimedia Services
  • Disclosure Services
  • Cision Communications Cloud®

About

  • About PR Newswire
  • About Cision
  • Partnering Opportunities
  • Careers
  • Accessibility Statement
  • APAC
  • APAC - Simplified Chinese
  • APAC - Traditional Chinese
  • Brazil
  • Canada
  • Czech
  • Denmark
  • Finland
  • France
  • Germany
  • India
  • Indonesia
  • Israel
  • Japan
  • Korea
  • Mexico
  • Middle East
  • Middle East - Arabic
  • Netherlands
  • Norway
  • Poland
  • Portugal
  • Russia
  • Slovakia
  • Spain
  • Sweden
  • United States
  • Vietnam

My Services

  • All News Releases
  • Customer Portal
  • Resources
  • Blog
  • Journalists
  • Data Privacy

Do not sell or share my personal information:

  • Submit via Privacy@cision.com 
  • Call Privacy toll-free: 877-297-8921

Contact PR Newswire

Products

About

My Services
  • All News Releases
  • Customer Portal
  • Resources
  • Blog
  • Journalists
+44 (0)20 7454 5110
from 8 AM - 5:30 PM GMT
  • Terms of Use
  • Privacy Policy
  • Information Security Policy
  • Site Map
  • RSS
  • Cookie Settings
Copyright © 2025 PR Newswire Europe Limited. All Rights Reserved. A Cision company.